Bristol Myers - Celgene CVRPreferred / convertible
13F holders, Q1 2026 (March 31)17holders −1
1new positions
2sold out
$0.12avg. 13F price*
At the end of Q1 2026, 17 institutions reported holding Bristol Myers - Celgene CVR in their 13F filings, down 1 from Q4 2025. 1 opened new positions and 2 sold out. The largest holders were Transcend Capital Advisors, LLC ($13K), DAVENPORT & Co LLC ($10K) and Bank of America Corp. ($6K).
- Company
- Bristol Myers - Celgene CVR
- CUSIP
- 110122140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 2 | $3K |
All 13F filers, Q4 2025 → Q1 2026: 20,388 shares bought and 45,611 shares sold, net −25,223 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Transcend Capital Advisors, LLC | — | No change | 109,175 | $13K |
| DAVENPORT & Co LLC | — | No change | 83,970 | $10K |
| Bank of America Corp. | — | Reduce -3.0% | 50,284 | $6K |
| Purkiss Capital Advisors LLC | — | No change | 26,450 | $3K |
| Fifth Third Bancorp | — | No change | 20,000 | $2K |
| Two Sigma Securities, LLC | — | New | 16,227 | $2K |
| Private Advisor Group, LLC | — | No change | 15,000 | $2K |
| UBS Group AG | — | Add +41610.0% | 4,171 | $484 |
| Northwestern Mutual Wealth Management Co. | — | No change | 341 | $39 |
| Rothschild Investment LLC | — | No change | 166 | $19 |
| Morgan Stanley | — | No change | 119 | $14 |
| Oakworth Capital, Inc. | — | No change | 125 | $14 |
| JPMorgan Chase & Co. | — | No change | 23 | $3 |
| Atlantic Edge Private Wealth Management, LLC | — | No change | 16 | $2 |
| Wells Fargo & Company | — | Reduce -64.3% | 10 | $1 |
| First Pacific Financial | — | No change | 6 | $1 |
| Royal Bank of Canada | — | No change | 2,475 | $0 |
"% of holder's portfolio" is BRISTOL MYERS - CELGENE CVR's weight in each manager's 13F, not the share of Bristol Myers - Celgene CVR the manager owns.